This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
Multi-kinase-IN-4
Catalog No. T78792
Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.18, and 2.09 μM. It exhibits broad-spectrum anti-cancer properties in HepG2, MCF-7, MDA-231, and HeLa cell lines, with IC50 values ranging from 1.94 to 7.1 µM, and demonstrates lower toxicity in WI-38 cells (IC50 = 40.85 µM). Additionally, it induces apoptosis and causes S-phase cell cycle arrest in HepG2 cells, and holds potential for cancer research [1].
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.18, and 2.09 μM. It exhibits broad-spectrum anti-cancer properties in HepG2, MCF-7, MDA-231, and HeLa cell lines, with IC50 values ranging from 1.94 to 7.1 µM, and demonstrates lower toxicity in WI-38 cells (IC50 = 40.85 µM). Additionally, it induces apoptosis and causes S-phase cell cycle arrest in HepG2 cells, and holds potential for cancer research [1].
Targets&IC50
CDK2:2.09 μM, VEGFR2:0.33 μM, HER2:0.18 mM
In vitro
Multi-kinase-IN-4 (compound 5d) demonstrates cytotoxicity against HepG2, MCF-7, MDA-231, and HeLa cell lines with IC50 values of 7.10, 2.48, 1.94, and 6.38 µM, respectively, after 48 hours of exposure, but exhibits lower cytotoxic activity towards WI38 cells (IC50 = 64.29 µM) [1]. When administered to HepG2 cells at a concentration of 7.1 µM for 24 hours, compound 5d increases the percentage of cells in S phase by 9.23% while decreasing the populations in G0-G1 and G2/M phases by 4.50% and 4.73%, respectively [1]. Additionally, Multi-kinase-IN-4 at 7.1 µM, over 24 hours, induces early and late apoptosis in HepG2 cells as well as necrotic cell death, with respective proportions of 7.51%, 3.45%, and 3.08% [1].
Molecular Weight
402.91
Formula
C21H20ClFN2OS
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Method for preparing DMSO master liquid: mg
drug pre-dissolved in μL DMSO (Master liquid concentration
mg/mL),
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL PEG300, mix and clarify, next add μL
Tween 80,mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL Corn oil,mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.